Literature DB >> 15662526

Relationship between intracellular localization of p34cdc2 protein and differentiation of esophageal squamous cell carcinoma.

T Nozoe1, I Takahashi, H Baba, Y Maehara.   

Abstract

PURPOSE: G2/M cyclins including cyclins A and B can exert their biologic functions of mitosis and proliferation of the tumor cells by being combined by protein kinase p34cdc2. The aim of the current study was to elucidate the clinicopathologic significance of immunohistochemical expression of p34(cdc2) in esophageal squamous cell carcinoma (ESCC), which has not been resolved.
METHODS: Immunohistochemical expression of p34(cdc2) was examined for 91 cases of ESCC, and the relationship between the type of p34(cdc2) expression and the clinicopathologic features of the patients and tumors was analyzed.
RESULTS: Forty-one ESCCs demonstrated cytoplasm dominant expression of p34(cdc2) and the other 50 ESCCs showed nuclei dominant p34(cdc2) expression. This differential expression pattern of p34(cdc2) did not reflect a prognostic aspect; however, the proportion of keratinizing tumors ESCCs with cytoplasm dominant expression of p34(cdc2) was significantly higher than that among ESCCs presenting nuclei-dominant p34(cdc2) expression (P=0.006).
CONCLUSION: Cellular differentiation in squamous cell carcinoma of the esophagus may be mediated by an intracellular localization of p34(cdc2).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15662526     DOI: 10.1007/s00432-004-0607-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  20 in total

1.  A new rapid immunohistochemical staining technique using the EnVision antibody complex.

Authors:  U Kämmerer; M Kapp; A M Gassel; T Richter; C Tank; J Dietl; P Ruck
Journal:  J Histochem Cytochem       Date:  2001-05       Impact factor: 2.479

2.  The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle.

Authors:  D W Goodrich; N P Wang; Y W Qian; E Y Lee; W H Lee
Journal:  Cell       Date:  1991-10-18       Impact factor: 41.582

3.  Clinicopathological significance of pRb2/p130 expression in squamous cell carcinoma of the esophagus.

Authors:  T Nozoe; D Korenaga; S Itoh; M Futatsugi; Y Maehara
Journal:  J Cancer Res Clin Oncol       Date:  2002-11-26       Impact factor: 4.553

4.  Expression of G2-M modulators in thyroid neoplasms: correlation of cyclin A, B1 and cdc2 with differentiation.

Authors:  Yasuhiro Ito; Hiroshi Yoshida; Keiichi Nakano; Yuuki Takamura; Kaoru Kobayashi; Tamotsu Yokozawa; Fumio Matsuzuka; Nariaki Matsuura; Kanji Kuma; Akira Miyauchi
Journal:  Pathol Res Pract       Date:  2002       Impact factor: 3.250

5.  Increased cdc2 and cdk2 kinase activity by retinoid X receptor gamma-mediated transcriptional down-regulation of the cyclin-dependent kinase inhibitor p21Cip1/WAF1 correlates with terminal differentiation of squamous cell carcinoma lines.

Authors:  D L Crowe; C F Shuler
Journal:  Cell Growth Differ       Date:  1998-08

6.  Expression of the G2-M modulators in pancreatic adenocarcinoma.

Authors:  Yasuhiro Ito; Tsutomu Takeda; Ken-ichi Wakasa; Masahiko Tsujimoto; Masanao Okada; Nariaki Matsuura
Journal:  Pancreatology       Date:  2002       Impact factor: 3.996

7.  p34cdc2 expression is an independent indicator for lymph node metastasis in colorectal carcinoma.

Authors:  T Nozoe; M Honda; S Inutsuka; D Korenaga
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-18       Impact factor: 4.553

Review 8.  Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle.

Authors:  E A Nigg
Journal:  Bioessays       Date:  1995-06       Impact factor: 4.345

9.  Identification of p34 and p13, human homologs of the cell cycle regulators of fission yeast encoded by cdc2+ and suc1+.

Authors:  G Draetta; L Brizuela; J Potashkin; D Beach
Journal:  Cell       Date:  1987-07-17       Impact factor: 41.582

10.  The retinoblastoma protein is phosphorylated on multiple sites by human cdc2.

Authors:  J A Lees; K J Buchkovich; D R Marshak; C W Anderson; E Harlow
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.